Syncom Formulations (India) quarterly results

Q1 FY27 · Apr–Jun 2026

₹ crore	Q1 FY27	Q1 FY26	Change
Revenue	126	117	+7.4%
EBITDA	26.2	15.8	+65.8%
EBITDA margin	20.9%	13.5%	+7.4 pts
Profit before tax	32.3	20.3	+58.9%
Net profit	24.8	15.8	+57.7%
EPS	₹0.26	₹0.21	+23.8%

Every quarter

₹ crore except per share

Tap a line for its trend	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024	Q4 FY24Mar 2024	Q3 FY24Dec 2023	Q2 FY24Sep 2023

Expenses
	126	135	115	122	117	149	128	102	87.3	74.6	65.1	63.8
	7.8	14.6	5.5	5.3	6.0	6.9	4.0	4.1	1.3	3.1	4.6	4.0
	133	150	121	127	123	156	132	106	88.6	77.7	69.7	67.8
	58.8	67.4	47.4	46.4	59.6	80.2	76.3	68.6	53.0	37.9	37.7	33.3
	18.2	20.5	15.7	15.3	15.7	15.8	7.2	12.7	4.3	5.0	4.5	8.4
	−11.2	−4.7	−2.1	9.0	−6.1	4.4	3.2	−15.4	−2.8	−0.2	−2.7	−2.5
	17.2	16.9	17.5	16.7	16.0	15.0	13.9	12.4	9.6	8.7	9.7	9.0
	0.2	0.4	0.3	0.3	0.3	0.1	0.2	0.2	0.4	1.2	1.1	1.1
	1.5	2.5	1.4	1.4	1.3	1.3	1.3	1.3	1.3	1.3	1.4	0.9
	16.3	13.1	15.4	15.8	16.0	15.8	12.2	11.9	12.6	13.8	8.5	9.3
	101	116	95.6	105	103	133	114	91.6	78.5	67.6	60.3	59.4
	26.2	22.0	21.2	18.4	15.8	17.8	14.7	12.2	10.5	9.4	7.4	6.4
	24.7	19.5	19.9	17.1	14.5	16.5	13.4	10.9	9.2	8.1	5.9	5.5
Profit
	32.3	33.7	25.1	22.0	20.3	23.3	17.3	14.9	10.1	10.0	9.4	8.4
	0.0	−0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	−0.0	0.0
	32.3	33.7	25.1	22.0	20.3	23.3	17.3	14.9	10.1	10.0	9.4	8.4
	7.3	7.4	6.0	5.1	4.3	4.6	4.2	3.5	2.4	2.6	2.3	1.5
	0.1	1.1	0.2	0.3	0.2	1.0	0.1	0.2	0.0	0.0	0.1	0.5
	7.4	8.5	6.2	5.4	4.5	5.6	4.3	3.7	2.5	2.6	2.4	1.9
	24.8	25.2	18.9	16.6	15.8	17.7	13.0	11.1	7.6	7.4	7.0	6.5
	24.8	25.2	18.9	16.6	15.8	17.7	13.0	11.1	7.6	7.4	7.0	6.5
	3.8	−10.0	2.4	−0.1	4.0	−2.3	0.2	3.9	2.8	1.6	1.9	1.2
	28.7	15.2	21.3	16.5	19.8	15.4	13.2	15.0	10.4	9.1	8.9	7.8
	—	25.2	—	16.6	—	—	13.0	—	—	—	—	—
Per share
	₹0.26	₹0.27	₹0.23	₹0.18	₹0.21	₹0.16	₹0.14	₹0.16	₹0.11	₹0.10	₹0.09	₹0.08
	₹0.26	₹0.27	₹0.23	₹0.18	₹0.21	₹0.16	₹0.14	₹0.16	₹0.11	₹0.10	₹0.09	₹0.08
Other comprehensive income — detail
	3.8	−10.0	2.4	−0.1	4.0	−2.3	—	—	—	—	—	—
	3.8	−10.0	2.4	−0.1	4.0	−2.3	0.2	3.9	2.8	1.6	1.9	1.2
	—	—	—	16.6	—	—	13.0	—	—	—	—	—
Per share — as-filed variants
	₹0.26	₹0.27	₹0.23	₹0.18	₹0.21	₹0.16	₹0.14	₹0.16	₹0.11	₹0.10	₹0.09	₹0.08
	₹0.26	₹0.27	₹0.23	₹0.18	₹0.21	₹0.16	₹0.14	₹0.16	₹0.11	₹0.10	₹0.09	₹0.08
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	59.7	52.1	54.1	51.0	47.7	48.5	40.9	36.5	32.7	31.9	25.6	24.7
	47.5%	38.5%	47.0%	41.9%	40.8%	32.6%	32.1%	35.7%	37.5%	42.7%	39.3%	38.7%
Adjusted (ex-exceptional items) — derived
	32.3	33.7	25.1	22.0	20.3	23.3	17.3	14.9	10.1	10.0	9.4	8.4
	0.0	−0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	−0.0	0.0
	24.8	25.2	18.9	16.6	15.7	17.7	13.0	11.1	7.6	7.4	7.0	6.5
	₹0.26	₹0.27	₹0.23	₹0.18	₹0.21	₹0.16	₹0.14	₹0.16	₹0.11	₹0.10	₹0.09	₹0.08

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

SYNCOMF₹20.33

Syncom Formulations (India) Limited

· Pharma & Health

Annual Quarterly₹ CrorePeersHESTERBIO NGLFINE WINDLAS JAGSNPHARMAMRUTANJAN INDOCO SAIPARENTMcap ₹1,911 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q2 FY24 30/09/2023	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026
Revenue from Operations	63.8	65.1	74.6	87.3	102.3	127.5	148.9	116.9	121.7	115.1	135.4	125.5
Other Income	4.0	4.6	3.1	1.3	4.1	4.0	6.9	6.0	5.3	5.5	14.6	7.8
Total Income	67.8	69.7	77.7	88.6	106.5	131.6	155.8	122.9	127.0	120.6	150.0	133.4
Expenses
+ Cost of Materials Consumed	33.3	37.7	37.9	53.0	68.6	76.3	80.2	59.6	46.4	47.4	67.4	58.8
+ Purchases of Stock-in-Trade	8.4	4.5	5.0	4.3	12.7	7.2	15.8	15.7	15.3	15.7	20.5	18.2
+ Changes in Inventories	-2.5	-2.7	-0.2	-2.8	-15.4	3.2	4.4	-6.1	9.0	-2.1	-4.7	-11.2
+ Employee Benefit Expense	9.0	9.7	8.7	9.6	12.4	13.9	15.0	16.0	16.7	17.5	16.9	17.2
+ Finance Costs	1.1	1.1	1.2	0.4	0.2	0.2	0.1	0.3	0.3	0.3	0.4	0.2
+ Depreciation & Amortisation	0.9	1.4	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	2.5	1.5
+ Other Expenses	9.3	8.5	13.8	12.6	11.9	12.2	15.8	16.0	15.8	15.4	13.1	16.3
Total Expenses	59.4	60.3	67.6	78.5	91.6	114.3	132.5	102.7	104.9	95.6	116.3	101.1
EBITDA	6.4	7.4	9.4	10.5	12.2	14.7	17.8	15.8	18.4	21.2	22.0	26.2
EBIT	5.5	5.9	8.1	9.2	10.9	13.4	16.5	14.5	17.1	19.9	19.5	24.7
Profit
PBT before Exceptional Items	8.4	9.4	10.0	10.1	14.9	17.3	23.3	20.3	22.0	25.1	33.7	32.3
+ Exceptional Items	0.0	-0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-0.0	0.0
Pretax Income	8.4	9.4	10.0	10.1	14.9	17.3	23.3	20.3	22.0	25.1	33.7	32.3
+ Current Tax	1.5	2.3	2.6	2.4	3.5	4.2	4.6	4.3	5.1	6.0	7.4	7.3
+ Deferred Tax	0.5	0.1	0.0	0.0	0.2	0.1	1.0	0.2	0.3	0.2	1.1	0.1
Tax Expense	1.9	2.4	2.6	2.5	3.7	4.3	5.6	4.5	5.4	6.2	8.5	7.4
Net Income	6.5	7.0	7.4	7.6	11.1	13.0	17.7	15.8	16.6	18.9	25.2	24.8
+ Net Income — Continuing Ops	6.5	7.0	7.4	7.6	11.1	13.0	17.7	15.8	16.6	18.9	25.2	24.8
+ Other Comprehensive Income	1.2	1.9	1.6	2.8	3.9	0.2	-2.3	4.0	-0.1	2.4	-10.0	3.8
Total Comprehensive Income	7.8	8.9	9.1	10.4	15.0	13.2	15.4	19.8	16.5	21.3	15.2	28.7
Net Income to Common	—	—	—	—	—	13.0	—	—	16.6	—	25.2	—
Per Share
Basic EPS	0.08	0.09	0.10	0.11	0.16	0.14	0.16	0.21	0.18	0.23	0.27	0.26
Diluted EPS	0.08	0.09	0.10	0.11	0.16	0.14	0.16	0.21	0.18	0.23	0.27	0.26
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	—	-2.3	4.0	-0.1	2.4	-10.0	3.8
+ Items to be Reclassified to P&L	1.2	1.9	1.6	2.8	3.9	0.2	-2.3	4.0	-0.1	2.4	-10.0	3.8
Comprehensive Income — Owners of Parent	—	—	—	—	—	13.0	—	—	16.6	—	—	—
Per Share — as-filed variants
Basic EPS — Continuing Operations	0.08	0.09	0.10	0.11	0.16	0.14	0.16	0.21	0.18	0.23	0.27	0.26
Diluted EPS — Continuing Operations	0.08	0.09	0.10	0.11	0.16	0.14	0.16	0.21	0.18	0.23	0.27	0.26
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	24.7	25.6	31.9	32.7	36.5	40.9	48.5	47.7	51.0	54.1	52.1	59.7
Gross Margin %	38.75	39.32	42.74	37.52	35.69	32.05	32.58	40.83	41.87	46.99	38.48	47.53
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	8.4	9.4	10.0	10.1	14.9	17.3	23.3	20.3	22.0	25.1	33.7	32.3
− Exceptional Items (reconciliation)	0.0	-0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-0.0	0.0
Net Income Adj (tax-effected)	6.5	7.0	7.4	7.6	11.1	13.0	17.7	15.7	16.6	18.9	25.2	24.8
EPS Adj	0.08	0.09	0.10	0.11	0.16	0.14	0.16	0.21	0.18	0.23	0.27	0.26
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Paid Up Equity Capital	94.0	94.0	94.0	94.0	94.0	94.0	94.0	94.0	94.0	94.0	94.0	94.0

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Syncom Formulations quarterly results

Syncom Formulations (NSE: SYNCOMF) has not yet announced the date of its Q2 FY27 results (July–September 2026); they are due by 14 November 2026 under SEBI's 45-day rule. Its latest results are for Q1 FY27 (April–June 2026). Consolidated net profit was ₹24.8 crore, up 57.7% from ₹15.8 crore in Q1 FY26 and down 1.3% from ₹25.2 crore in Q4 FY26. Revenue from operations was ₹126 crore, up 7.4% year on year and down 7.3% from the previous quarter.

Q2 FY26 results (a year earlier): 12 November 2025
Q1 FY27 results (the latest): 11 August 2026

Latest results: Q1 FY27 (Apr–Jun 2026) · consolidated

Q2 FY27 results due by: 14 November 202645 days after the quarter (SEBI)
Q1 FY27 net profit: ₹24.8 Cr+57.7% vs Q1 FY26−1.3% vs Q4 FY26
Q1 FY27 revenue: ₹126 Cr+7.4% vs Q1 FY26−7.3% vs Q4 FY26
Q1 FY27 operating margin: 19.7%+7.3 pts vs Q1 FY26+5.2 pts vs Q4 FY26
Q2 FY26 net profit (a year earlier): ₹16.6 CrRevenue ₹122 Cr
Q1 FY27 EPS (basic): ₹0.26

Questions

When will Syncom Formulations announce its Q2 FY27 results?

The date is not announced yet. Results for July–September 2026 are due by 14 November 2026 (45 days after the quarter, SEBI Regulation 33). Last year it reported Q2 FY26 on 12 November 2025.

What will Syncom Formulations' Q2 FY27 results be compared with?

With the same quarter a year earlier, Q2 FY26 (July–September 2025), when consolidated net profit was ₹16.6 crore and revenue from operations ₹122 crore. The latest quarter, Q1 FY27, had a net profit of ₹24.8 crore and revenue of ₹126 crore.

What was Syncom Formulations' net profit in FY26?

Consolidated net profit was ₹76.4 crore in FY26 (April 2025–March 2026), up 54.6% from ₹49.4 crore in FY25. It was ₹25.3 crore in FY24 and ₹20.1 crore in FY23: up 280.8% over three years, 56.2% a year on average.

What were Syncom Formulations' Q1 FY27 results?

Consolidated net profit was ₹24.8 crore, up 57.7% from ₹15.8 crore in Q1 FY26 and down 1.3% from ₹25.2 crore in Q4 FY26. Revenue from operations was ₹126 crore, up 7.4% year on year and down 7.3% from the previous quarter.

How has Syncom Formulations' profit changed over the last four quarters?

Net profit by quarter: ₹16.6 crore in Q2 FY26, ₹18.9 crore in Q3 FY26, ₹25.2 crore in Q4 FY26 and ₹24.8 crore in Q1 FY27. That is ₹85.5 crore over the four quarters, up 48.6% from ₹57.6 crore in the four quarters before. Revenue from operations: ₹122 crore, ₹115 crore, ₹135 crore and ₹126 crore.

What was Syncom Formulations' revenue in FY26?

Revenue from operations was ₹489 crore in FY26 (April 2025–March 2026), up 5.2% from ₹465 crore in FY25. It was ₹263 crore in FY24 and ₹224 crore in FY23: up 118.1% over three years, 29.7% a year on average.

Where do these Syncom Formulations figures come from?

From Syncom Formulations' own consolidated results filings to NSE, in ₹ crore as filed; the date from its board-meeting notices.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.